A Phase 1, Open Label Study to Characterize the Absorption, Metabolism and Excretion of 14C-JNJ-53718678 After a Single Dose in Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 14 Apr 2017 Status changed from recruiting to completed.
- 01 Mar 2017 Status changed from not yet recruiting to recruiting.
- 29 Dec 2016 New trial record